A Study to Evaluate Safety and Efficacy of Ocrelizumab in Comparison With Fingolimod in Children and Adolescents With Relapsing-Remitting Multiple Sclerosis (RRMS)
Public ClinicalTrials.gov record NCT05123703. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase III Multicenter, Randomized, Double-blind, Double-dummy Study to Evaluate Safety and Efficacy of Ocrelizumab in Comparison With Fingolimod in Children and Adolescents With Relapsing-Remitting Multiple Sclerosis
Study identification
- NCT ID
- NCT05123703
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 3
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Enrollment
- 188 participants
Conditions and interventions
Conditions
Interventions
- Ocrelizumab Drug
- Ocrelizumab Placebo Other
- Fingolimod Drug
- Fingolimod Placebo Other
Drug · Other
Eligibility (public fields only)
- Age range
- 10 Years to 17 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- May 18, 2022
- Primary completion
- Jun 8, 2025
- Completion
- Sep 16, 2029
- Last update posted
- Jan 29, 2026
2022 – 2029
United States locations
- U.S. sites
- 13
- U.S. states
- 11
- U.S. cities
- 13
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| UC San Diego | La Jolla | California | 92037-1337 | — |
| University of California San Francisco | San Francisco | California | 94117 | — |
| Children's Hospital Colorado | Aurora | Colorado | 80045 | — |
| Children's National Hospital | Washington D.C. | District of Columbia | 20010 | — |
| Johns Hopkins Medicine | Baltimore | Maryland | 21287 | — |
| Boston Children's Hospital Central Pharmacy | Boston | Massachusetts | 02115-5724 | — |
| Washington University | St Louis | Missouri | 63101 | — |
| Robert Wood Johnson Medical School | New Brunswick | New Jersey | 08901 | — |
| Cleveland Clinic, Mellen Center for Multiple Sclerosis | Cleveland | Ohio | 44195-0001 | — |
| The Boster Center for Multiple Sclerosis a Singlepoint Healthcare Company | Columbus | Ohio | 43235 | — |
| The Children's Hospital of Philadelphia | Philadelphia | Pennsylvania | 19104 | — |
| Baylor College of Medicine/Texas Children's Hospital | Houston | Texas | 77030-2608 | — |
| University of Virginia Health System | Charlottesville | Virginia | 22903 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 89 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05123703, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jan 29, 2026 · Synced Jun 25, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT05123703 live on ClinicalTrials.gov.